close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

226.87 +0.65 (+0.29%)
Official Closing Price Updated: 7:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Is the Vanguard Value ETF the Simplest Way to Consistently Collect More Passive Income Than the S&P 500?
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
3 Market-Beating Stocks with Solid Fundamentals
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules
The federal court dismissed a lawsuit from business chambers over the Medicare drug price negotiation program. 
Via Benzinga
Topics Lawsuit
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Expert Outlook: AbbVie Through The Eyes Of 4 Analysts
 
Via Benzinga
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. 
Via Benzinga
Topics Economy
Federal Reserve Poised for Rate Cuts as Economic Headwinds Mount, Tariffs Complicate Outlook
Financial markets are currently pricing in a high likelihood of the Federal Reserve initiating interest rate cuts before the year-end, a significant shift in monetary policy that reflects growing... 
Via MarketMinute
Topics Bankruptcy Economy Government
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far. 
Via Benzinga
Topics Government World Trade
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
AbbVie (ABBV) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
AbbVie Raises 2025 Outlook After Q2 Beat
Via The Motley Fool
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics
 
Via Benzinga
Topics Economy Government
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month. 
Via The Motley Fool
Topics Intellectual Property
3 Dividend Champion Stocks I'm Watching in 2025
Other investors might want to watch these high-yield dividend stocks, too. 
Via The Motley Fool
Topics Earnings Government World Trade
Why AbbVie Stock Flew Higher on Friday
A solid quarterly earnings report reverberated though the pundit community that day. 
Via The Motley Fool
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
AbbVie raised full-year guidance after Q2 sales beat expectations, with analysts lifting price targets despite an earnings miss. 
Via Benzinga
Topics Earnings
Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining
Big-name bidders, strategic reviews, and PE exits define an active, high-stakes M&A market so far this summer. 
Via Benzinga
5 Dividend Stocks With Solid Returns And More Growth Ahead
 
Via Benzinga
Why AbbVie (ABBV) Stock Is Up Today
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year... 
Via StockStory
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
These pharmaceutical giants are well worth a second look. 
Via The Motley Fool
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Why AbbVie Stock Slumped Today
An encouraging quarterly earnings report was dampened by a new demand from President Trump. 
Via The Motley Fool
Topics Government
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook 
Via MarketBeat
AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier
AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while full-year earnings guidance was raised. 
Via Benzinga
AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic
For the full year, the company raised its adjusted and diluted earnings per share guidance to $11.88 to $12.08, up from its previous guidance of $11.67 to $11.87. 
Via Stocktwits
Topics Intellectual Property
AbbVie Inc (NYSE:ABBV) Beats Q2 2025 Earnings and Revenue Estimates, Raises Full-Year Guidance
AbbVie beats Q2 2025 revenue and EPS estimates, raises full-year outlook. Stock surges 4.59% pre-market on strong portfolio performance and pipeline progress. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today